# OLMA catalysts: Olema Oncology, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/olma/catalysts

> Olema Oncology, Inc. (OLMA) has 7 upcoming catalysts. The next is the palazestrant interim data readout, Dec 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Olema Oncology, Inc. |
| Ticker | OLMA (Nasdaq) |
| SEC CIK | 1750284 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/olma |

## Cash runway

Cash $413.8M as of 2026-09-30; quarterly burn $47.1M; about 26.3 months of runway at that rate (XBRL company facts, accession 0001193125-26-454421).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan 2024 | [OP-3136 trial start](https://sec-api.dev/pdufa/op-3136) | OLMA | ER+/HER2- metastatic breast cancer and other cancers | completed | "In January 2024, we nominated a development candidate for this program, OP-3136 and in late 2024, the IND application for OP-3136 was cleared by the FDA and we initiated a Phase 1 clinical trial evaluating OP-3136 in patients with ER+/HER2- metastatic breast cancer and other cancers." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)) |
| November 12, 2024 | [Olema Oncology, Inc. earnings report](https://sec-api.dev/companies/olma/catalysts) | OLMA |  | completed | "Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000095017024125384/olma-ex99_1.htm)) |
| early 2025 | [OP-3136 trial start](https://sec-api.dev/pdufa/op-3136) | OLMA |  | scheduled | "Olema has successfully completed IND-enabling studies in support of a potential Investigational New Drug (IND) application with the FDA and expects to initiate Phase 1 clinical trials for OP-3136 in early 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000095017024125384/olma-ex99_1.htm)) |
| March 18, 2025 | [Olema Oncology, Inc. earnings report](https://sec-api.dev/companies/olma/catalysts) | OLMA |  | completed | "SAN FRANCISCO, March 18, 2025 (Globe NewsWire) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the fourth quarter and full year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000095017025041186/olma-ex99_1.htm)) |
| May 13, 2025 | [Olema Oncology, Inc. earnings report](https://sec-api.dev/companies/olma/catalysts) | OLMA |  | completed | "SAN FRANCISCO, May 13, 2025 (GlobeNewswire) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the first quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000095017025070291/olma-ex99_1.htm)) |
| Q3 2025 | [OPERA-02 trial start](https://sec-api.dev/pdufa/opera-02) | OLMA |  | scheduled | "We also expect to initiate OPERA-02, a proposed Phase 3 clinical trial of palazestrant in combination with a CDK4/6 inhibitor, ribociclib, in the third quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1750284/000095017025106565/olma-20250630.htm)) |
| August 11, 2025 | [Olema Oncology, Inc. earnings report](https://sec-api.dev/companies/olma/catalysts) | OLMA |  | completed | "SAN FRANCISCO, August 11, 2025 (GlobeNewswire) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the second quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000095017025106545/olma-ex99_1.htm)) |
| November 10, 2025 | [Olema Oncology, Inc. earnings report](https://sec-api.dev/companies/olma/catalysts) | OLMA |  | completed | "SAN FRANCISCO, November 10, 2025 (GlobeNewswire) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the third quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000119312525273228/olma-ex99_1.htm)) |
| 2026 | [OP-3136 topline data readout](https://sec-api.dev/pdufa/op-3136) | OLMA |  | scheduled | "With initial clinical results from OP-3136 anticipated in Q22026, top-line data from OPERA-01 expected in the fall of this year, and commercial launch preparations underway for a potential approval in late 2027, we are entering an exciting chapter in Olema's history." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107154/olma-ex99_1.htm)) |
| 2026 | [KISQALI® (ribociclib) topline data readout](https://sec-api.dev/pdufa/ribociclib) | OLMA |  | scheduled | "On track for top-line data in 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000095017024134759/olma-ex99_3.htm)) |
| March 16, 2026 | [Olema Oncology, Inc. earnings report](https://sec-api.dev/companies/olma/catalysts) | OLMA |  | completed | "SAN FRANCISCO, March 16, 2026 (Globe NewsWire) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the fourth quarter and full year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107154/olma-ex99_1.htm)) |
| May 12, 2026 | [Olema Oncology, Inc. earnings report](https://sec-api.dev/companies/olma/catalysts) | OLMA |  | completed | "SAN FRANCISCO, May 12, 2026 (Globe NewsWire) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the first quarter ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526218142/olma-ex99_1.htm)) |
| May 30, 2026 | [OP-3136 interim data readout](https://sec-api.dev/pdufa/op-3136) | OLMA |  | scheduled | "As previously announced, Olema will present initial clinical data from the Phase 1 study of OP-3136 in a poster presentation on May 30, 2026 at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526237832/olma-ex99_1.htm)) |
| 2H 2026 | [OPERA-01 topline data readout](https://sec-api.dev/pdufa/opera-01) | OLMA |  | scheduled | ""Having achieved regulatory alignment on the selected dose for our pivotal palazestrant program during the second quarter, we are focused on accelerating enrollment in OPERA-01, which is on track for top-line data in the second half of 2026, and initiating the OPERA-02 combination trial in the frontline setting," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000095017025106545/olma-ex99_1.htm)) |
| 2H 2026 | [Olema Oncology, Inc. topline data readout](https://sec-api.dev/companies/olma/catalysts) | OLMA |  | scheduled | "We anticipate top-line results for this trial in the second half of 2026, expect to submit the New Drug Application in 2027, and, if successful, anticipate U.S. Food and Drug Administration ("FDA") approval and commercial launch in late 2027." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1750284/000119312525288287/d846460d424b5.htm)) |
| August 10, 2026 | [Olema Oncology, Inc. earnings report](https://sec-api.dev/companies/olma/catalysts) | OLMA |  | completed | "SAN FRANCISCO, August 10, 2026 (Globe NewsWire) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526342334/olma-ex99_1.htm)) |
| Oct 2026 to Jan 2027 | [Palazestrant topline data readout](https://sec-api.dev/pdufa/palazestrant) | OLMA | Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer | scheduled | "NCT06016738 (OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor Olema Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06016738)) |
| October 2026 | [Palazestrant primary completion](https://sec-api.dev/pdufa/palazestrant) | OLMA | Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer | delayed | "NCT06016738 (OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor Olema Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06016738)) |
| November 10, 2026 | [Olema Oncology, Inc. earnings report](https://sec-api.dev/companies/olma/catalysts) | OLMA |  | completed | "SAN FRANCISCO, November 10, 2026 (Globe NewsWire) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the third quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454403/olma-ex99_1.htm)) |
| Dec 2026 | [Palazestrant interim data readout](https://sec-api.dev/pdufa/palazestrant) | OLMA |  | scheduled | "The Phase 1b/2 study investigating palazestrant in combination with atirmociclib has completed enrollment and we expect to present initial data at the San Antonio Breast Cancer Symposium (SABCS) in December 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)) |
| 2027 | [OP-3136 topline data readout](https://sec-api.dev/pdufa/op-3136) | OLMA |  | scheduled | "We expect initial clinical results from the OP-3136 Phase 1 study in mid-2026, potential additional data readout in 2027, and potential initiation of a Phase 3 clinical trial in 2028." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1750284/000119312525288287/d846460d424b5.htm)) |
| Q1 2027 | [OPERA-01 topline data readout](https://sec-api.dev/pdufa/opera-01) | OLMA |  | scheduled | "On track to announce top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454403/olma-ex99_1.htm)) |
| 2028 | [OPERA-02 topline data readout](https://sec-api.dev/pdufa/opera-02) | OLMA |  | scheduled | "We expect to initiate OPERA-02 in the third quarter of 2025, anticipate top-line data in 2028, and anticipate potential approval and commercial launch in the frontline MBC setting in the U.S. in 2029." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1750284/000095017025106565/olma-20250630.htm)) |
| 2028 | [OP-3136 trial start](https://sec-api.dev/pdufa/op-3136) | OLMA |  | scheduled | "We expect initial clinical results from the OP-3136 Phase 1 study in mid-2026, potential additional data readout in 2027, and potential initiation of a Phase 3 clinical trial in 2028." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1750284/000119312525288287/d846460d424b5.htm)) |
| December 2028 | [Palazestrant primary completion](https://sec-api.dev/pdufa/palazestrant) | OLMA | Breast Cancer; Locally Advanced Breast Cancer; Metastatic Breast Cancer | scheduled | "NCT07085767 (Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Olema Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07085767)) |
| Dec 2028 to Mar 2029 | [Palazestrant topline data readout](https://sec-api.dev/pdufa/palazestrant) | OLMA | Breast Cancer; Locally Advanced Breast Cancer; Metastatic Breast Cancer | scheduled | "NCT07085767 (Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Olema Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07085767)) |

## Drugs

- [OP-3136](https://sec-api.dev/pdufa/op-3136): er+/her2- metastatic breast cancer and other cancers
- [OPERA-01](https://sec-api.dev/pdufa/opera-01): 
- [OPERA-02](https://sec-api.dev/pdufa/opera-02): 
- [Palazestrant](https://sec-api.dev/pdufa/palazestrant): second- and third-line metastatic breast cancer, Breast Cancer

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/olma/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "OLMA catalysts: Olema Oncology, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/olma/catalysts

```bibtex
@misc{secapidev_companies_olma_catalysts_20261116,
  title        = {OLMA catalysts: Olema Oncology, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/olma/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_olma_catalysts_20261116","title":"OLMA catalysts: Olema Oncology, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/olma/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
